About this item:

446 Views | 616 Downloads

Author Notes:

Correspondence: agopal@u.washington.edu

Subjects:

Research Funding:

This study was supported by Gilead Sciences, Inc. Editorial assistance for the development of this manuscript was provided by Meryl Gersh, PhD, of AlphaBioCom, LLC, King of Prussia, PA, and funded by Gilead Sciences, Inc., Foster City, CA.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • NON-HODGKINS-LYMPHOMA
  • INDOLENT LYMPHOMA
  • UNITED-STATES
  • MULTICENTER
  • SURVIVAL

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Show all authors Show less authors

Journal Title:

Haematologica

Volume:

Volume 102, Number 4

Publisher:

, Pages E156-E159

Type of Work:

Article | Final Publisher PDF

Copyright information:

© 2017 Ferrata Storti Foundation

Export to EndNote